ARTICLE | Clinical News
MGI Pharma ovarian cancer data
April 6, 2000 7:00 AM UTC
MOGN said preliminary PhaseII results for its Irofulven hydroxymethylacylfulvene ( MGI 114) showed efficacy in 15 patients with ovarian cancer who had failed other therapies. Five patients showed a pa...